IRIS
BONATI, Antonio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.777
AS - Asia 3.139
EU - Europa 2.051
SA - Sud America 324
AF - Africa 145
Continente sconosciuto - Info sul continente non disponibili 36
OC - Oceania 7
Totale 9.479
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.648
SG - Singapore 1.100
CN - Cina 1.011
VN - Vietnam 428
IT - Italia 393
IE - Irlanda 310
SE - Svezia 276
FI - Finlandia 260
DE - Germania 243
BR - Brasile 242
UA - Ucraina 217
HK - Hong Kong 203
TR - Turchia 109
BD - Bangladesh 104
NL - Olanda 99
CA - Canada 89
ZA - Sudafrica 86
FR - Francia 65
GB - Regno Unito 59
IN - India 39
JP - Giappone 38
RU - Federazione Russa 32
CI - Costa d'Avorio 27
AR - Argentina 25
AT - Austria 16
ES - Italia 16
BE - Belgio 15
EC - Ecuador 14
IQ - Iraq 13
KR - Corea 13
MX - Messico 13
CO - Colombia 12
ID - Indonesia 12
VE - Venezuela 11
PL - Polonia 10
CL - Cile 8
CZ - Repubblica Ceca 8
EE - Estonia 7
LT - Lituania 7
MA - Marocco 7
PK - Pakistan 7
SA - Arabia Saudita 7
AU - Australia 6
DZ - Algeria 6
TT - Trinidad e Tobago 6
CR - Costa Rica 5
KE - Kenya 5
MY - Malesia 5
PH - Filippine 5
BO - Bolivia 4
IR - Iran 4
JO - Giordania 4
KG - Kirghizistan 4
NI - Nicaragua 4
PT - Portogallo 4
PY - Paraguay 4
TW - Taiwan 4
UZ - Uzbekistan 4
AE - Emirati Arabi Uniti 3
BG - Bulgaria 3
RO - Romania 3
SC - Seychelles 3
TH - Thailandia 3
TN - Tunisia 3
UY - Uruguay 3
AM - Armenia 2
CH - Svizzera 2
DO - Repubblica Dominicana 2
JM - Giamaica 2
LV - Lettonia 2
LY - Libia 2
MN - Mongolia 2
NG - Nigeria 2
NP - Nepal 2
OM - Oman 2
PA - Panama 2
PS - Palestinian Territory 2
SX - ???statistics.table.value.countryCode.SX??? 2
AZ - Azerbaigian 1
BN - Brunei Darussalam 1
CU - Cuba 1
CY - Cipro 1
EG - Egitto 1
ET - Etiopia 1
GE - Georgia 1
GR - Grecia 1
GT - Guatemala 1
HN - Honduras 1
HU - Ungheria 1
IL - Israele 1
KW - Kuwait 1
LB - Libano 1
LC - Santa Lucia 1
LK - Sri Lanka 1
LU - Lussemburgo 1
MD - Moldavia 1
ML - Mali 1
MZ - Mozambico 1
NZ - Nuova Zelanda 1
PE - Perù 1
Totale 9.442
Salva come PNG Salva come JPEG
Città #
Singapore 539
San Jose 371
Chandler 326
Jacksonville 322
Ashburn 317
Dublin 309
Santa Clara 304
Beijing 265
Hong Kong 193
Council Bluffs 159
Dallas 153
Nanjing 116
Ho Chi Minh City 112
Boardman 106
Ann Arbor 105
Hanoi 105
Parma 99
Izmir 91
Dearborn 87
Johannesburg 84
San Mateo 71
Princeton 70
Los Angeles 60
Lauterbourg 55
New York 54
Toronto 54
Jinan 49
Wilmington 47
Hebei 41
Munich 41
Shenyang 40
Bologna 39
Hefei 36
Tokyo 36
Shanghai 33
Des Moines 31
Helsinki 31
Nanchang 30
Abidjan 27
Kunming 27
São Paulo 27
Moscow 26
Da Nang 23
Milan 23
Columbus 21
Changsha 19
Guangzhou 19
Haiphong 19
Düsseldorf 18
Montreal 18
Woodbridge 17
Buffalo 16
Tianjin 16
Brussels 15
Phoenix 15
Atlanta 14
London 14
Turku 14
Zhengzhou 14
Amsterdam 13
Nuremberg 13
Pittsburgh 13
Washington 13
Falls Church 12
Brooklyn 11
Fremont 11
Grafing 11
Haikou 11
Rio de Janeiro 11
Rome 11
Seattle 11
Chennai 10
Houston 10
Kocaeli 10
Orem 10
Taizhou 10
The Dalles 10
Hải Dương 9
Jiaxing 9
Lanzhou 9
Leawood 9
North Bergen 9
Vienna 9
Chicago 8
Denver 8
Fuzhou 8
Seoul 8
Warsaw 8
Baghdad 7
Boston 7
Bremen 7
Chengdu 7
Hangzhou 7
Poplar 7
Porto Alegre 7
Redmond 7
Trezzano Sul Naviglio 7
Biên Hòa 6
Borås 6
Can Tho 6
Totale 5.759
Salva come PNG Salva come JPEG
Nome #
Functional interplay between NIK and c-Abl kinases limits response to Aurora inhibitors in multiple myeloma 331
MEK1/2 KINASES DISABLE THE TUMOR SUPPRESSOR FUNCTIONS OF NATIVE BCR AND ABL1 KINASES TO IMPAIR ANTICANCER DRUGS’ RESPONSIVENESS IN TKI-RESISTANT PHILADELPHIA POSITIVE LEUKEMIAS 290
MEK-INHIBITORS/ARSENIC TRIOXIDE COMBINATION THERAPY AS A NOVEL TREATMENT OPTION FOR TYROSINE KINASE INHIBITORS-RESISTANT PH+-LEUKEMIA 273
Acenaphthenequinone thiosemicarbazone and its transition metal complexes: synthesis, structure, and biological activity. 175
Early proinflammatory activation of renal tubular cells by normal and pathologic IgG 166
MEK-INHIBITORS/ARSENIC TRIOXIDE COMBINATION THERAPY AS A NOVEL TREATMENT OPTION FOR TYROSINE KINASE INHIBITORS-RESISTANT PH plus -LEUKEMIA 162
Elevated telomerase activity, minimal telomere loss in cord blood long-term cultures with extensive stem cell replication 162
Aurora and IKK kinases cooperatively interact to protect multiple myeloma cells from Apo2L/TRAIL 159
Downmodulation of ERK protein kinase activity inhibits VEGF secretion by human myeloma cells and myeloma-induced angiogenesis 155
The new tumor suppressor gene inhibitor of growth family member 4 (ING4) regulates the production of pro-angiogenic molecules by myeloma cells and suppresses hypoxia inducible factor (HIF)-1{alpha} activity being involved in myeloma-induced angiogenesis. 153
p73 and p53 pathway in human breast cancers. 149
Biochemical, Immunological, and Molecular Markers of Hemopoietic Precursor Cells. 148
Targeting the cancer initiating cell: the ultimate target for cancer therapy. 146
A micro-mechanically motivated model for the strength of heat-treated glass 146
Treatment with Arsenic Trioxide (ATO) and MEK1 inhibitor activates the p73-p53AIP1 apoptotic pathway in leukemia cells 144
Emerging MEK inhibitors 140
Arsenic Trioxide (ATO) and MEK1 inhibition synergize to induce apoptosis in acute promyelocytic leukemia cells 139
T cell receptor genes: a glance at normal and malignant hematopoiesis. 137
Combined treatment with the MEK inhibitor PD0325901 and Arsenic Trioxide has potent anti-tumor activity in vivo against human multiple myeloma xenograft model. 134
Emerging Raf inhibitors 133
Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. 133
Downmodulation of ERK activity inhibits the proliferation and induces the apoptosis of primary acute myelogenous leukemia blasts 132
Arsenic Trioxide in hematological malignancies: the new discovery of an ancient drug. 130
Calibration of the Statistical-Interference Factors for the Design of Tempered Structural Glass 129
MDM2 inhibition synergistically enhances cytotoxicity of MEK1 inhibitor and Arsenic Trioxide (ATO) in AML blasts that retain a functional p53 pathway 129
MEK1/2 regulate normal BCR and ABL1 tumor-suppressor functions to dictate ATO response in TKI-resistant Ph+ leukemia 127
Lung cancer in patients with chronic lymphocytic leukemia: does the HER-2 oncogene play a role? 127
BCL2 oncogene protein expression in human hematopoietic precursors during fetal life. 126
Discordant expression of terminal transferase and T cell receptor beta chain in fetal and pediatric thymocytes. 126
Detection of the common acute lymphoblastic leukaemia antigen (CALLA) on B cells from human fetal tissues. A multiple phenotypic characterization. 125
Ph1-positive acute myelocytic leukemia with high TdT levels. 125
Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia 124
Effect of the protein tyrosine kinase inhibitor genistein on normal and leukaemic haemopoietic progenitor cells. 123
Terminal deoxynucleotidyl transferase (TdT) levels in hairy cell leukemia. 122
Human T-cell receptor alpha chain gene during ontogeny 121
Pan-aurora kinase inhibitor MK-0457 synergistically potentiates Apo2l/TRAIL cytotoxicity in Multiple Mieloma cells sensitive and resistant to bortezomib 121
Selection of myeloid progenitors lacking BCR/ABL mRNA in chronic myelogenous leukemia patients after in vitro treatment with the tyrosine kinase inhibitor genistein. 119
T-cell receptor beta-chain gene rearrangement and expression during human thymic ontogenesis. 118
Su di un caso di sclerodermia associato ad aplasia midollare globale. 118
Expression and activation of SHC/MAP kinase pathway in primary acute myeloid leukemia blasts. 117
Synthesis, characterisation, X-ray structure and biological activity of three new 5-formyluracil thiosemicarbazone complexes 116
MEK-ERK pathway is expressed but not activated in high proliferating, self-renewing cord blood hematopoietic progenitors 114
Synthesis, spectroscopic characterization and biological properties of new natural aldehydes thiosemicarbazones 111
Expression of TCR beta chain gene N-diversity is not an early event in human thymic ontogeny 110
Terminal deoxynucleotidyl transferase: a nuclear marker of hemopoietic precursors. Biochemical, immunological and clinical aspects. 110
Synthesis, structure, spectroscopic properties and biological activity of mixed diorganotin(IV) complexes containing pyridine-2-carbaldehyde thiosemicarbazonato and diphenyldithiophosphinato ligands. 109
Espressione degli antigeni CD1a, CD1b, CD1c in timo umano a diverse eta' dello sviluppo. 108
Phorbol ester-induced PKC{epsilon} down-modulation sensitizes AML cells to TRAIL-induced apoptosis and cell differentiation. 107
Role of GSTP1-1 in mediating the effect of As2O3 in the Acute Promyelocytic Leukemia cell line NB4. 107
Valutazione dell'attivita proliferativa delle cellule emopoietiche nelle sindromi preleucemiche. 104
Hemopoiesis during human fetal life. Present knowledge and future prospects. 103
Terminal deoxynucleotidyl transferase (TDT) expression correlates with the presence of N regions during human thymic ontogeny 102
La linfoadenopatia angio-immunoblastica: Osservazioni cliniche, patologiche ed immunologiche su di un caso. 102
Expression of the T1 (CD5, p67) surface antigen in B-CLL and B-NHL and its correlation with other B-cell differentiation markers. 101
Targeting the Raf/MEK/ERK pathway with small-molecule inhibitors. 101
Targeting MEK/MAPK signal transduction module potentiates ATO-induced apoptosis in multiple myeloma cells through multiple signaling pathways 100
The fine structure of HNK-1 (Leu7) positive cells. A study using an immunoperoxidase technique. 98
Phenotype of the terminal transferase-positive cells in human foetal liver and bone-marrow: analysis with monoclonal antibodies. 98
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. 98
Terminal deoxynucleotidyl transferase-positive B cell precursors in fetal lymph nodes and extrahemopoietic tissues. 97
La mielofibrosi idiopatica asplenomegalica. Osservazioni cliniche e considerazioni su cinque casi. 97
Terminal deoxynucleotidyl transferase in human fetal tissues. 96
TCR beta chain expression during human thymic development. 95
The combination of MEK inhibitors and Arsenic Trioxide triggers in vitro and in vivo synergistic cytotoxicity in multiple myeloma through multiple signaling pathways 94
Philadelphia-positive chronic myelogenous leukemia with typical bcr/abl molecular features and atypical, prolonged survival. 94
MEK1 inhibition sensitizes primary acute myelogenous leukemia to arsenic trioxide-induced apoptosis 91
Selective Expression and Constitutive Phosphorylation of SHC Proteins in the CD34+ Fraction of Chronic Myelogenous Leukemias. 89
Progression of a myelodysplastic syndrome to pre-B acute lymphoblastic leukaemia with unusual phenotype. 88
Terminal deoxynucleotidyl transferase (TdT) in human foetuses. An immunofluorescent and biochemical study. 84
Regulation of proliferation and cytokine expression of bone marrow fibroblasts: role of c-myb. 82
Medicina molecolare: nuovi strumenti per la conoscenza e la cura delle patologie dell'uomo. 81
Leu-7-positive cells with monocyte phenotype show different ultrastructural features in comparison to Leu-7-positive cells with T-cell phenotype. 81
Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy. 80
The p53 family protein p73 provides new insights into cancer chemosensitivity and targeting. 78
Combined Treatment with the Mek Inhibitor PD0325901 and Arsenic Trioxide Has Potent Antitumor Activity in Vivo against Human Multiple Myeloma Xenograft Model 67
Combined treatment with the MEK inhibitor PD0325901 and Arsenic Trioxide has potent antitumor activity in NOD-SCID mice bearing advanced tumors of human multiple myeloma. 53
THE COMBINATION OF MEK INHIBITORS AND ARSENIC TRIOXIDE TRIGGERS IN VITRO AND IN VIVO SYNERGISTIC CYTOTOXICITY IN MULTIPLE MYELOMA THROUGH MULTIPLE SIGNALING PATHWAYS 52
Arsenic Trioxide (ATO) Interacts Synergistically with MEK Inhibitors to Induce Apoptosis in STI571-Resistant Bcr-Abl Mutants 47
Totale 9.479
Salva come PNG Salva come JPEG
Categoria #
all - tutte 32.995
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 32.995
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022351 0 0 0 0 12 16 63 72 20 34 18 116
2022/20231.154 138 121 92 86 102 121 5 67 372 14 28 8
2023/2024402 33 47 17 7 54 68 23 9 15 22 34 73
2024/20251.590 59 91 104 60 208 197 30 74 215 138 114 300
2025/20263.122 281 273 343 243 390 202 409 135 388 220 161 77
2026/2027628 66 176 159 209 18 0 0 0 0 0 0 0
Totale 9.479